Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026
Same author

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Nature communications·2026
Same author

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

HemaSphere·2026
Same author

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Clinical pharmacology and therapeutics·2026
Same author

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Blood advances·2026
Same author

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Nature medicine·2026

Related Experiment Video

Updated: Sep 23, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K

MRD in multiple myeloma: does CR really matter?

Bruno Paiva1, Jesus San-Miguel1, Hervé Avet-Loiseau2,3

  • 1Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Centro de Cáncer Universidad de Navarra, Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain.

Blood
|May 13, 2022
PubMed
Summary
This summary is machine-generated.

Deeper responses in multiple myeloma correlate with longer survival. However, some patients with persistent M protein achieve undetectable minimal residual disease (MRD), highlighting conflicting response criteria.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Related Experiment Videos

Last Updated: Sep 23, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • The depth of response in multiple myeloma is linked to patient survival.
  • Conflicting data exist regarding complete remission (CR) and minimal residual disease (MRD) negativity.
  • Some patients with persistent M protein demonstrate undetectable MRD, posing a challenge to current response assessment.

Approach:

  • Reviewing the frequency of discordance between M protein levels and MRD status.
  • Analyzing the outcomes of patients exhibiting this discordance.
  • Investigating potential explanations and clinical consequences of conflicting response criteria.

Key Points:

  • Discordance between M protein and MRD negativity occurs in multiple myeloma.
  • Understanding this discordance is crucial for accurate prognostication.
  • Persistent M protein with undetectable MRD presents a unique clinical scenario.

Conclusions:

  • Minimal residual disease (MRD) assessment should be considered in clinical trials for patients achieving very good partial response (VGPR) or better.
  • Standardizing response criteria in multiple myeloma is essential for consistent clinical trial interpretation.
  • Further research is needed to elucidate the implications of M protein persistence alongside MRD negativity.